数据
资源
版本对比
免费注册
预约演示
免费注册
Taiho Oncology
and
Astex Pharmaceuticals
Announce Data Presentations at the 65th ASH Annual Meeting
2023-11-17
·
BioSpace
ASH会议
[17-November-2023] Real-world evidence on use of oral
decitabine
and
cedazuridine
in the treatment of
myelodysplastic syndromes
to be featured in an oral presentation; results of several additional studies in
hematological malignancies
were accepted for poster presentations PRINCETON, N.J. and PLEASANTON, Calif., Nov. 17, 2023 /PRNewswire/ --
Taiho Oncology Inc.
and
Astex Pharmaceuticals, Inc.
announced today details of studies to be presented at the 65th American Society of Hematology (ASH) Annual Meeting, to be held Dec. 9-12, 2023, in San Diego. Among these data are the results of a real-world study of oral
decitabine
and
cedazuridine
in patients with
myelodysplastic syndromes (MDS)
, which will be featured in an oral presentation. "Real-world data in healthcare is invaluable as it provides us with a closer look at actual patient experiences outside the clinical trial setting," said Tehseen Salimi, MD, MHA, Senior Vice President Medical Affairs,
Taiho Oncology
Oncology
. "This study is the first to explore how an oral therapy may help patients with
MDS
adhere to their treatment regimen, while reducing both personal and disease burden. Oral
decitabine
and
cedazuridine
is a potentially important treatment option for people living with this form of
cancer
." Below are viewing details of this oral presentation. The above study was sponsored by
Taiho Oncology
. In addition, investigational compounds from
Astex Pharmaceuticals
that are currently in various stages of clinical development will be featured in several poster presentations. The above studies are being sponsored by
Astex Pharmaceuticals, Inc.
About
Taiho Oncology, Inc.
The mission of
Taiho Oncology, Inc.
is to improve the lives of patients with
cancer
, their families and their caregivers. The company specializes in the development and commercialization of orally administered anti-
cancer
agents for various
tumor
types.
Taiho Oncology
has a robust pipeline of small molecule clinical candidates targeting
solid tumor
and
hematological malignancies
, with additional candidates in pre-clinical development.
Taiho Oncology
is a subsidiary of
Taiho Pharmaceutical Co., Ltd.
which is part of
Otsuka Holdings Co., Ltd.
Taiho Oncology
is headquartered in Princeton, New Jersey and oversees its parent company's European and Canadian operations, which are located in Zug, Switzerland and Oakville, Ontario, Canada. For more information, visit , and follow us on LinkedIn and Twitter. About
Astex Pharmaceuticals, Inc.
Astex Pharmaceuticals, Inc.
is committed to the fight against
cancer
.
Astex
is developing a proprietary pipeline of novel therapies for the treatment of
solid tumors
and
hematological malignancies
.
Astex
is a member of the
Otsuka group
of companies. The group also includes
Otsuka Pharmaceutical Co., Ltd.
,
Taiho Pharmaceutical Co., Ltd.
, and
Taiho Oncology, Inc.
Astex
, the
Astex
logo,
Taiho Oncology
, and the
Taiho Oncology
logo are registered trademarks of
Otsuka Holdings Co., Ltd.
or its subsidiaries.
Taiho Oncology
Contact: Judy Kay Moore (574) 526-2369 jumoore@taihooncology.com
Astex Pharmaceuticals
: Martin Buckland
Astex Pharmaceuticals, Inc.
(+1) 925-560-0100 martin.buckland@astx.com INQ-PM-US-0512 1 Investigational Oral
DNA Methyltransferase Inhibitor
DNA Methyltransferase
Inhibitor 2
X-Linked Inhibitor of Apoptosis Protein (XIAP)/Cellular
Inhibitor of Apoptosis Protein (cIAP) Antagonist -
Astex Pharmaceuticals, Inc.
investigational agent being developed in collaboration with
Taiho Oncology, Inc.
更多内容,
请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点,如有版权侵扰或错误之处,请及时联系我们,我们会在24小时内配合处理。
机构
Taiho Oncology, Inc.
Astex Pharmaceuticals, Inc.
Taiho Pharmaceutical Co., Ltd.
[+4]
适应症
实体瘤
血液肿瘤
肿瘤
[+1]
靶点
DNMTS
XIAP
药物
地西他滨
西达尿苷
QTX-200 series (Quimatryx)
标准版
¥
16800
元/账号/年
新药情报库 | 省钱又好用!
立即使用
热门报告
全球潜力靶点及FIC产品研究调研报告
智慧芽生物医药
肿瘤领域药物开发早期热门靶点研究报告(AACR 2023-2024)
智慧芽生物医药
siRNA药物Amvuttra专利调研实务指南
智慧芽生物医药
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台,助您全方位提升您的研发与决策效率。
开始免费试用
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台,以API或者数据包形式对外开放,助您更加充分利用智慧芽新药情报信息。
试用数据服务